Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/6943
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alpan, A.S. | - |
dc.contributor.author | Zencir, Sevil | - |
dc.contributor.author | Zupkó, I. | - |
dc.contributor.author | Coban, G. | - |
dc.contributor.author | Rthy, B. | - |
dc.contributor.author | Gunes, H.S. | - |
dc.contributor.author | Topcu, Z. | - |
dc.date.accessioned | 2019-08-16T12:13:18Z | - |
dc.date.available | 2019-08-16T12:13:18Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1475-6366 | - |
dc.identifier.uri | https://hdl.handle.net/11499/6943 | - |
dc.identifier.uri | https://doi.org/10.1080/14756360802420831 | - |
dc.description.abstract | Benzimidazoles of both natural and synthetic sources are the key components of many bio-active compounds. Several reports have shown antifungal, antiviral, H2 receptor blocker and antitumor activities for benzimidazoles and their derivatives. In this study, we synthesized twelve bis-benzimidazole derivatives by selecting di(1H-benzo[d]imidazol-2-yl)methane as the main compound. The numbers of carbons at 2 positions of bis-benzimidazole derivatives were changed from 1 to 4, and derivatives were synthesized with methyl substitutions at 5- and/or 6- positions. The compounds were screened via in vitro plasmid superciol relaxation assays using mammalian DNA topoisomerase I and cytostatic assays were carried out against HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma) and A431 (skin epidermoid carcinoma) cells for selected derivatives. Our results suggest that the malonic acid derivatives of bis-benzimidazoles, namely, bis(5-methyl-1H-benzo[d]imidazol-2-yl)methane and bis(5,6-dimethyl-1H-benzo[d] imidazol-2-yl)methane, were remarkably active compounds in interfering with DNA topoisomerase I and the former compound was also found to be cytotoxic against MCF7 and A431 cells. The inhibitory effects obtained with these derivatives are significant as these compounds can be potential sources of anticancer agents. © 2009 Informa UK Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Informa Healthcare | en_US |
dc.relation.ispartof | Journal of Enzyme Inhibition and Medicinal Chemistry | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Bis-benzimidazoles | en_US |
dc.subject | Cytotostaticity | en_US |
dc.subject | DNA topoisomerase I | en_US |
dc.subject | 1,2 bis(5 methyl 1h benzo[d]imidazol 2 yl)ethane | en_US |
dc.subject | 1,2 bis(5,6 dimethyl 1h benzo[d]imidazol 2 yl) ethane | en_US |
dc.subject | 1,2 di(1h benzo[d]imidazol 2 yl)ethane | en_US |
dc.subject | 1,3 bis(5 methyl 1h benzo[d]imidazol 2 yl)propane | en_US |
dc.subject | 1,3 bis(5,6 dimethyl 1h benzo[d]imidazol 2 yl)propane | en_US |
dc.subject | 1,3 di(1h benzo[d]imidazol 2 yl)propane | en_US |
dc.subject | 1,4 bis(5 methyl 1h benzo[d]imidazol 2 yl)butane | en_US |
dc.subject | 1,4 bis(5,6 dimethyl 1h benzo[d]imidazol 2 yl)butane | en_US |
dc.subject | 1,4 di(1h benzo[d]imidazol 2 yl)butane | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | benzimidazole derivative | en_US |
dc.subject | bis(5 methyl 1h benzo[d ]imidazol 2 yl)methane | en_US |
dc.subject | bis(5 methyl 1h benzo[d]imidazol 2 yl)methane | en_US |
dc.subject | bis(5,6 dimethyl 1h benzo[d]imidazol 2 yl)methane | en_US |
dc.subject | carbon | en_US |
dc.subject | di(1h benzo[d ]imidazol 2 yl)methane | en_US |
dc.subject | di(1h benzo[d]imidazol 2 yl)methane | en_US |
dc.subject | DNA topoisomerase | en_US |
dc.subject | malonic acid derivative | en_US |
dc.subject | methyl group | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | bis-benzimidazole | en_US |
dc.subject | DNA topoisomerase inhibitor | en_US |
dc.subject | adenocarcinoma | en_US |
dc.subject | article | en_US |
dc.subject | biological activity | en_US |
dc.subject | breast adenocarcinoma | en_US |
dc.subject | cancer cell | en_US |
dc.subject | controlled study | en_US |
dc.subject | cytostasis | en_US |
dc.subject | cytotoxicity | en_US |
dc.subject | drug inhibition | en_US |
dc.subject | drug screening | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | human | en_US |
dc.subject | human cell | en_US |
dc.subject | in vitro study | en_US |
dc.subject | plasmid | en_US |
dc.subject | priority journal | en_US |
dc.subject | skin carcinoma | en_US |
dc.subject | squamous cell carcinoma | en_US |
dc.subject | substitution reaction | en_US |
dc.subject | animal | en_US |
dc.subject | breast tumor | en_US |
dc.subject | chemistry | en_US |
dc.subject | female | en_US |
dc.subject | HeLa cell line | en_US |
dc.subject | metabolism | en_US |
dc.subject | pathology | en_US |
dc.subject | spectroscopy | en_US |
dc.subject | structure activity relation | en_US |
dc.subject | synthesis | en_US |
dc.subject | tumor cell line | en_US |
dc.subject | uterine cervix tumor | en_US |
dc.subject | Mammalia | en_US |
dc.subject | Animals | en_US |
dc.subject | Antineoplastic Agents | en_US |
dc.subject | Benzimidazoles | en_US |
dc.subject | Breast Neoplasms | en_US |
dc.subject | Carcinoma, Squamous Cell | en_US |
dc.subject | Cell Line, Tumor | en_US |
dc.subject | DNA Topoisomerases, Type I | en_US |
dc.subject | Female | en_US |
dc.subject | HeLa Cells | en_US |
dc.subject | Humans | en_US |
dc.subject | Spectrum Analysis | en_US |
dc.subject | Structure-Activity Relationship | en_US |
dc.subject | Topoisomerase I Inhibitors | en_US |
dc.subject | Uterine Cervical Neoplasms | en_US |
dc.title | Biological activity of bis-benzimidazole derivatives on DNA topoisomerase i and HeLa, MCF7 and A431 cells | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 24 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 844 | - |
dc.identifier.startpage | 844 | en_US |
dc.identifier.endpage | 849 | en_US |
dc.identifier.doi | 10.1080/14756360802420831 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 18951286 | en_US |
dc.identifier.scopus | 2-s2.0-70749151860 | en_US |
dc.identifier.wos | WOS:000266040700030 | en_US |
dc.identifier.scopusquality | Q2 | - |
dc.owner | Pamukkale University | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | 06.01. Clinical Sciences | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
49
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
43
checked on Nov 21, 2024
Page view(s)
48
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.